"Between 2000 and 2050, there are expected to be an extra billion people aged 65 or older. This will inevitably lead to a large increase in disorders of old age, particularly diseases of the brain. Central nervous system (CNS) drugs entering clinical development have just a 1 percent chance of reaching the market place, compared with the industry average of 11 percent, and they also take longer to get there. All this leaves us with a central paradox: Age-related disorders of the brain present a massive and increasing unmet medical need, and yet the CNS represents the therapeutic area associated with the greatest challenge and highest risk at a time when the industry is under intense financial pressure and struggles to deliver the double-digit growth that investors have come to expect."

Objective1:Inform the audience of the latest developments.

Objective2:Redefine healthy aging and why we should modify our thinking about chronic disease.

Objective3:Promote partnerships among those who are the cornerstone of the health-care system: governments, payers, health-care professionals, academic and scientific institutions and industry.